MULTIFOCAL DIFFERENTIATED THYROID CANCER
DOI:
https://doi.org/10.32471/oncology.2663-7928.t-21-2-2019-g.7401Keywords:
invasion, metastases, multifocal differentiated thyroid carcinomas, relapses, МАСISAbstract
Aim: the purpose of the paper is to determine the frequency of multifocal thyroid cancer wide-spreading for tumors with different characteristics. Materials and Methods: a retrospective study of patients’ cohort has been carried out including persons operated because of thyroid cancer. The patients were divided into groups according to such characteristics as uni- and multifocality. While analyzing patients’ age and sex, as well as histological types of carcinomas, their sizes, tumor characteristics according to the TNM (tumor, nodus, metastasis) classification and invasive properties, clinical stage of disease, volume of surgical intervention, prognosis according to the MACIS scale, and mortality levels have been taken into account. Results: the significant difference between unifocal and multifocal papillary and follicular carcinomas was observed in the elderly (above 60 years) patients, whereas multifocal follicular carcinomas are almost absent in patients below 18. It has been found that the wide-spreading of papillary multifocal carcinomas with aggressive characteristics is higher comparing to unifocal carcinoma. The changes among cohort patients’ percent with follicular carcinomas when multifocal growth is present or absent are similar to papillary carcinomas-associated changes. But the degree of these probability changes is not so marked, especially concerning the changes of patients percent with follicular carcinomas of different sizes, different T categories, different clinical stages. Simultaneously, the mortality of patients with multifocal follicular carcinomas exceeds this index for cases with multifocal papillary carcinomas. It may be due to two times higher percent of elderly patients with multifocal follicular carcinomas comparing to patients with papillary. This is a cause of higher risk degree for relapse development and frequency, of poorer prognosis as well as of differences for patients treatment tactics with multifocal tumors. Conclusion: multifocality is an important factor determining the survival prognosis for patients with differentiated thyroid carcinomas.
References
Qu N, Zhang L, Ji Q,et al. Number of tumor foci predicts prognosis in papillary thyroid cancer. BMC Cancer 2014; 14: 914.
Kim K, Kin S, Lee Y, et al. Prognostic significance of tumor multifocality in papillary thyroid carcinoma and its relationship with primary tumor size: a retrospective study of 2,309 consecutive patients. Ann Surg Oncol 2015; 22 (1): 125–31.
Lin J, Chen S, Chao T, et al. Diagnosis and therapeutic strategy of papillary thyroid microcarcinoma. Arch Surg 2005; 140 (10): 940–5.
Kiriakopoulos A, Petralias A, Linos D. Multifocal versus solitary papillary thyroid carcinoma. World J Surg 2016; 40 (9): 2139–43.
Haugen B, Alexander E, Bible K, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 2016; 26 (1): 1–133.
Wang W, Su X, He K, et al. Comparison of the clinicopathologic features and prognosis of bilateral versus unilateral multifocal papillary thyroid cancer: an updated study with more than 2000 consecutive patients. Cancer 2016; 122 (2): 198–206.
Kuo S, Lin S, Chao T, et al. Prognosis of multifocal papillary thyroid carcinoma. Inter J Endocrinol 2013; 2013: ID 809382: 6 p.
Dunki-Jacobs E, Grannan K, McDonough S, et al. Clinically unsuspected papillary microcarcinomas of the thyroid: a common finding with favorable biology? Amer J Surgery 2012; 203 (2): 140–4.
Tam A, Özdemir D, Çuhacı N, et al. Association of multifocality, tumor number, and total tumor diameter with clinicopathological features in papillary thyroid cancer. Endocrine 2016; 53 (3): 774–83.
Ng S-C, Kuo S-F, Chen S-T, et al. Therapeutic outcomes of patients with multifocal papillary thyroid microcarcinomas and larger tumors. Inter J Endocrinol 2017; 2017: ID 4208178: 8.
Genpeng L, Jianyong L, Jiaying Y, et al. Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer. Medicine (Baltimore) 2018; 97 (5): e9619.
Guda B, Kovalenko A, Bolgov M, et al. Main prognostic factors for well differentiated thyroid cancer: Analysis of combined patients treatment results during 20 years after surgery. Thyroid Disorders Ther 2018; 7: 228.
Tam A, Ozdemir D, Ogmen B, et al. Should multifocal papillary thyroid carcinomas classified as T1a with a tumor diameter sum of 1 to 2 centimeters be reclassified as T1b? Endocr Pract 2017; 23 (5): 526–35.
Yan W, Jiang T, Zheng X. An analysis of features and risk factors for neck lymph node metastasis in papillary thyroid carcinoma. Chinese J Modern Oncol 2017; 5: 709–12.
Zhi J, Zhao J, Gao M, et al. Impact of major different variants of papillary thyroid microcarcinoma on the clinicopathological characteristics: the study of 1041 cases. Int J Clin Oncol 2018; 23 (1): 59–65.
Joseph K, Edirimanne S, Eslick G. Multifocality as a prognostic factor in thyroid cancer: A meta-analysis. Int J Surg 2018; 50: 121–5.18. Ali A, Abdelhameed H. Papillary thyroid carcinoma, evaluation of prophylactic central compartment’s dissection versus conservative management: a prospective study. Int Surg J 2018; 5 (2): 383–9.
Hu D, Zhou J, He W, et al. Risk factors of lateral lymph node metastasis in cN0 papillary thyroid carcinoma. World J Surg Oncol 2018; 16: 30.
Kim Y, Roh J-L, Gong G, et al. Risk factors for lateral neck recurrence of N0/N1a papillary thyroid cancer. Ann Surg Oncol 2017; 24 (12): 3609–16.
Liu L-S, Liang J, Li J-H, et al. The incidence and risk factors for central lymph node metastasis in cN0 papillary thyroid microcarcinoma: a meta-analysis. Eur Arch Otorhinolaryngol 2017; 274 (3): 1327–38.
Tang T, Li J, Zheng L, et al. Risk factors of central lymph node metastasis in papillary thyroid carcinoma: A retrospective cohort study. Int J Surg 2018; 54 (Pt A): 129–32.
Sessa L, Lombardi C, De Crea C, et al. Risk factors for central neck lymph node metastases in micro-versus macro-clinically node negative papillary thyroid carcinoma. World J Surg 2018; 42 (3): 623–9.
Xu Y, Xu L, Wang J. Clinical predictors of lymph node metastasis and survival rate in papillary thyroid microcarcinoma: analysis of 3607 patients at a single institution. J Surg Res 2018; 221: 128–34.
Zhao S, Ma Y, Yin Z, et al. Evaluation of central lymph node dissection for papillary thyroid carcinoma in cN0 T1/T2. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2018; 53 (2): 105–9.
Spinelli C, Tognetti F, Strambi S, et al. Cervical lymph node metastases of papillary thyroid carcinoma, in the central and lateral compartments, in children and adolescents: Predictive factors. World J Surg 2018; 42 (8): 2444–53.
So Y, Kim M-J, Kim S, et al. Lateral lymph node metastasis in papillary thyroid carcinoma: A systematic review and meta-analysis for prevalence, risk factors, and location. Int J Surg 2018; 50: 94–103.
Lee Y, Park K, Park S, et al. Association between diffuse lymphocytic infiltration and papillary thyroid cancer aggressiveness according to the presence of thyroid peroxidase antibody and BRAFV600E mutation. Head Neck 2018; 40 (10): 2271–9.
Myshunina T, Guda B, Bolgov M, et al. Differentiated thyroid carcinomas associated with chronic thyroiditis: biological and clinical properties. Exp Oncol 2018; 40 (2): 128–31.
Chuang J. Telomerase reverse transcriptase promoter mutation and its clinical implication in thyroid cancer. Precision Future Med 2018; 2 (1): 8–17.
Feng J, Gan X, Shen F, et al. The role of two tumor foci for predicting central lymph node metastasis in papillary thyroid carcinoma: A meta-analysis. Int J Surg 2018; 52: 166–70.
Wang F, Yu X, Shen X, et al. The prognostic value of tumor multifocality in clinical outcomes of papillary thyroid cancer. J Clin Endocrinol Metab 2017; 102 (9): 3241–50.
Su H, Li Y. Factors related to lymph node recurrence in patients with N1b papillary thyroid carcinoma after unilateral therapeutic modified radical neck dissection: A meta-analysis. Zentralbl Chir 2018; 143 (4): 373–9.
Nam S, Roh J-L, Gong G, et al. Nodal factors predictive of recurrence after thyroidectomy and neck dissection for papillary thyroid carcinoma. Thyroid 2018; 28 (1): 88–95.
Zhang A, Liu L, Lu C, et al. Risk factors of central neck lymph node metastasis in cNO papillary thyroid carcinoma. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2017; 31 (15): 1141–5.
Zhang X, Su X, Chen W, et al. RET/PTC rearrangement affects multifocal formation of papillary thyroid carcinoma. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2017; 52 (6): 435–9.
Cordioli M, Moraes L, Bastos A, et al. Fusion oncogenes are the main genetic events found in sporadic papillary thyroid carcinomas from children. Thyroid 2017; 27 (2): 182–8.
Wang W, Wang H, Teng X, et al. Clonal analysis of bilateral, recurrent, and metastatic papillary thyroid carcinomas. Human Pathology 2010; 41 (9): 1299–309.
Aherne S, Smyth P, Flavin R, et al. Geographical mapping of a multifocal thyroid tumour using genetic alteration analysis and miRNA profiling. Mol Cancer 2008; 7: 89.
Kuhn E, Teller L, Piana S, et al. Different clonal origin of bilateral papillary thyroid carcinoma, with a review of the literature. Endocrine Pathol 2012; 23 (2): 101–7.
Lu Z, Sheng J, Zhang Y, et al. Clonality analysis of multifocal papillary thyroid carcinoma by using genetic profiles. J Pathol 2016; 239 (1): 72–83.
Krčálová E, Horáček J, Kudlej L, et al. Is radioiodine administration in patients with papillary thyroid multifocal microcarcinoma unnecessary? Endocrin Diabetes Metab Case Rep 2016; 2016: 150138.
Spinelli C, Rallo L, Morganti R, et al. Surgical management of follicular thyroid carcinoma in children and adolescents: A study of 30 cases. J Pediatr Surg 2018; 54 (3): 521–6.
Kim J, Roh J-L, Gong G, et al. Extent of extrathyroidal extension as a significant predictor of nodal metastasis and extranodal extension in patients with papillary thyroid carcinoma. Ann Surg Oncol 2017; 24 (2): 460–8.
